相关实验视频

Updated: May 1, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

响应pH的聚碳酸纳米平台可实现对非小细胞肺癌疗法进行增强的异位级联协同作用的顺序释放

Jinghang Li¹, Hao Liao², Shuangyu Tian²

¹School of Chemistry, Chemical Engineering and Life Science, Wuhan University of Technology, Wuhan 430070, China; State Key Laboratory of Advanced Technology for Materials Synthesis and Processing, Wuhan University of Technology, Wuhan, 430070, China; Shenzhen Institute of Wuhan University of Technology, Shenzhen 518000, China.

Acta biomaterialia

|September 4, 2025

概括

这项研究开发了适应pH的纳米颗粒,用于顺序输送erlotinib和doxorubicin,增强癌症治疗效果. 这种新型纳米平台在体外和体内显著改善了瘤抑制,为精确瘤学提供了有前途的方法.

科学领域:

生物医学工程
材料科学
癌症学

背景情况:

瘤异质性挑战了有效的癌症单一疗法.
连续使用药物可以增强协同治疗效果.
埃尔洛替尼能使瘤对像多克索鲁比辛这样的DNA损伤剂产生敏感性.

研究的目的:

开发一个响应pH的纳米平台,用于对erlotinib和doxorubicin的时空控制.
研究顺序释放药物机制及其对抗瘤功效的影响.
在非小细胞肺癌模型中评估纳米平台的治疗潜力.

主要方法:

开发一种双酸响应的聚合物纳米平台 (PEDHNPs) 具有和连接.
在纳米载体内封装erlotinib和 doxorubicin.
药物释放的体外评价,抗增殖和益的作用.
在非小细胞肺癌小鼠模型中的瘤体积减少的体内评估.

主要成果:

PEDHNP 显示了 pH 触发的 erlotinib 序列释放,其次是 doxorubicin.
与单一治疗相比,PEDHNP的体外研究显示出明显更高的增殖抑制.
在体内用PEDHNP治疗导致95. 1%的瘤体积减少.
通过酶-8介导的亡来增强多克索鲁比辛的抗瘤作用.

结论:

开发的PEDHNP为癌症治疗中精确,顺序的药物输送提供了多功能平台.
这种策略克服了单一治疗的局限性,并提高了组合治疗的疗效.
这种纳米平台对推进精确瘤学和改善患者的治疗结果具有显著的前景.

关键词:

聚碳酸盐顺序交付协同疗法响应 pH 的

更多相关视频

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

相关概念视频

Modified-Release Drug Delivery Systems: Site-Targeted

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...